Hematemesis medical therapy

Jump to navigation Jump to search

Hematemesis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hematemesis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Hematemesis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Hematemesis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Hematemesis medical therapy

CDC on Hematemesis medical therapy

Hematemesis medical therapy in the news

Blogs on Hematemesis medical therapy

Directions to Hospitals Treating Hematemesis

Risk calculators and risk factors for Hematemesis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: John Fani Srour, M.D.

Overview

Medical Therapy

Treatment of hematesis depends on the underlying cause. The goal of medical therapy is to correct shock and coagulation abnormalities and to stabilize the patient so that further evaluation and treatment can proceed.

  • Stop diet, stabilize the patient with intravenous fluids, and transfuse to maintain a hemoglobin level of 8-10 g/dl, if necessary. Promptly correct any abnormalities in coagulation.
  • Intravenous PPIs are the ideal pharmacologic therapy for patients with acute ulcer bleeding and rebleeding.
  • Upper endoscopy can be used to treaat the active bleed.

General Management

The most common causes of upper GI bleeding include bleeding peptic ulcer disease, gastritis, and variceal bleed related to hepatic cirrhosis. This management section discusses general treatment of bleeding related to these common causes: In general, individuals who are at low risk for recurrent or life-threatening hemorrhage may be suitable for early hospital discharge or even outpatient care. All patients with hemodynamic instability or active bleeding should be admitted to an intensive care unit for resuscitation and close observation. Two large caliber peripheral catheters or a central venous line should be inserted for intravenous access. Gastroenterological consultation should be obtained. A surgical consultation can be obtained in high-risk patients. These patients should also receive packed red blood cell transfusions to maintain the hematocrit above 30 percent. In general, patients with upper GI bleeding (high and low risk patients) should be treated with an intravenous Protein pump inhibitor (PPI) at presentation until confirmation of the cause of bleeding, after which the need for specific therapy can be determined. Protein pump inhibitors are used because the most common causes of GI bleed are gastritis and peptic ulcer disease. Patients known to have cirrhosis who present with upper GI bleeding should receive antibiotics, preferably before endoscopy, as bacterial infections are present in up to 20 percent of these patients. Somatostatin may also reduce the risk of bleeding due to variceal and nonvariceal causes.

References

Template:WikiDoc Sources